Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia

from PharmacoEconomics at http://bit.ly/2nqbHmc on January 31, 2018 at 07:21PM Abstract Background Severe hypercholesterolemia is a major risk factor of death in patients with coronary heart disease. New adjunctive drug therapies (proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors) have gained approval in Europe and the USA. Objective In this empirical study, we documented preferences regarding […]